AI Engines For more Details: Perplexity Kagi Labs You
Histamine Regulation: Spaglumic acid acts as an inhibitor of histamine release from mast cells. Histamine is a chemical released by the immune system during allergic reactions. By inhibiting histamine release, spaglumic acid helps to reduce allergic symptoms such as itching, sneezing, runny nose, and watery eyes.
Anti-Allergic Effects: Spaglumic acid is primarily used to alleviate symptoms associated with allergic conditions, including allergic rhinitis (hay fever), allergic conjunctivitis, and allergic dermatitis. It can help relieve itching, redness, swelling, and other allergic reactions by modulating the release of histamine.
Asthma Management: Spaglumic acid has been used as an adjunctive treatment for asthma. While it is not a bronchodilator like some other asthma medications, it may help to reduce airway inflammation and hyperresponsiveness, which are common features of asthma exacerbations triggered by allergies.
Tolerability: Spaglumic acid is generally well-tolerated, with a low incidence of side effects. Unlike some other antihistamine medications, it is less likely to cause sedation or drowsiness, making it suitable for daytime use without impairing alertness or cognitive function.
Non-Sedating Antihistamine: Spaglumic acid belongs to the class of non-sedating or second-generation antihistamines. These medications are preferred over first-generation antihistamines due to their lower potential for causing sedation and other central nervous system side effects.
Minimal Anticholinergic Effects: Unlike some antihistamines, spaglumic acid has minimal anticholinergic effects, which reduces the risk of side effects such as dry mouth, blurred vision, constipation, and urinary retention. This makes it suitable for use in individuals who may be sensitive to anticholinergic medications.
Safety Profile: Spaglumic acid has been used for decades in the management of allergic conditions and asthma, and it is generally considered safe when used as directed. However, as with any medication, there is a potential for adverse effects, and individuals should be monitored for any signs of intolerance or allergic reactions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.5 | 0.5 | |
| Age-Related Macular Degeneration and Glaucoma | 0 | 0.3 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.9 | 0.9 | |
| Allergies | 0.2 | 0.5 | -1.5 |
| Allergy to milk products | 0.5 | 0.4 | 0.25 |
| Alopecia (Hair Loss) | 0.5 | 0.5 | |
| Alzheimer's disease | 0.4 | 0.3 | 0.33 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.1 | 0.5 | -4 |
| Ankylosing spondylitis | 1 | 0.7 | 0.43 |
| Anorexia Nervosa | 0.3 | 0.3 | 0 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 0 | 0 | |
| Atherosclerosis | 0.2 | 0 | 0 |
| Atrial fibrillation | 0.6 | 0.4 | 0.5 |
| Autism | 2 | 0.8 | 1.5 |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Bipolar Disorder | 0.6 | 0.3 | 1 |
| Brain Trauma | 0 | 0 | |
| Carcinoma | 0.8 | 0.5 | 0.6 |
| Celiac Disease | 0.4 | 0.5 | -0.25 |
| Cerebral Palsy | 0.1 | 0.3 | -2 |
| Chronic Fatigue Syndrome | 1.7 | 0.6 | 1.83 |
| Chronic Kidney Disease | 0.9 | 0 | 0 |
| Chronic Lyme | 0 | 0 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0 | 0 |
| Chronic Urticaria (Hives) | 0.5 | 0.5 | |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.4 | 0.75 |
| Colorectal Cancer | 1.1 | 1.1 | |
| Constipation | 0.1 | 0 | 0 |
| Coronary artery disease | 0.7 | 0.7 | |
| COVID-19 | 1 | 1.2 | -0.2 |
| Crohn's Disease | 1.3 | 0.5 | 1.6 |
| cystic fibrosis | 0.3 | 0 | 0 |
| deep vein thrombosis | 0.3 | 0.4 | -0.33 |
| Depression | 2.1 | 0.8 | 1.63 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.6 | 0.4 | 0.5 |
| Endometriosis | 0.7 | 0.2 | 2.5 |
| Epilepsy | 0.2 | 0.3 | -0.5 |
| Fibromyalgia | 0.3 | 0.3 | |
| Functional constipation / chronic idiopathic constipation | 0.9 | 0 | 0 |
| gallstone disease (gsd) | 0.6 | 0 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | -0.1 | |
| Generalized anxiety disorder | 0.8 | 0.8 | |
| Glioblastoma | 0.1 | -0.1 | |
| Graves' disease | 0.3 | 0 | 0 |
| Halitosis | 0.1 | -0.1 | |
| Hashimoto's thyroiditis | 0 | 0 | |
| Hidradenitis Suppurativa | 0.1 | 0.1 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 0.2 | 0 |
| hyperglycemia | 0.1 | 0.3 | -2 |
| hypertension (High Blood Pressure | 0.8 | 0.1 | 7 |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.5 | -0.5 | |
| Inflammatory Bowel Disease | 1.2 | 1.3 | -0.08 |
| Insomnia | 0.1 | 0 | 0 |
| Intracranial aneurysms | 0.5 | 0.5 | |
| Irritable Bowel Syndrome | 0.6 | 0.3 | 1 |
| Liver Cirrhosis | 0.8 | 0.4 | 1 |
| Long COVID | 1.7 | 1 | 0.7 |
| Low bone mineral density | 0 | 0 | |
| Lung Cancer | 0.1 | 0.2 | -1 |
| ME/CFS with IBS | 0.8 | 0.8 | |
| ME/CFS without IBS | 0.8 | 0.5 | 0.6 |
| Metabolic Syndrome | 1.5 | 0.7 | 1.14 |
| Mood Disorders | 2.3 | 0.8 | 1.87 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
| Multiple Sclerosis | 0.9 | 1.2 | -0.33 |
| Multiple system atrophy (MSA) | 0.2 | -0.2 | |
| Neuropathy (all types) | 0.1 | 0.1 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.2 | 0.2 | 0 |
| Obesity | 1.3 | 0.8 | 0.63 |
| obsessive-compulsive disorder | 1.2 | 0.5 | 1.4 |
| Osteoarthritis | 0.7 | 0.2 | 2.5 |
| Osteoporosis | 0.4 | 0.4 | |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 0.6 | 0.5 | 0.2 |
| Polycystic ovary syndrome | 0.6 | 0.5 | 0.2 |
| Premenstrual dysphoric disorder | 0.3 | -0.3 | |
| Psoriasis | 0.6 | 0.8 | -0.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.3 | 0 | 0 |
| Rosacea | 0.2 | 0 | 0 |
| Schizophrenia | 0.5 | 0.3 | 0.67 |
| scoliosis | 0.2 | -0.2 | |
| Sjögren syndrome | 0.5 | 0.3 | 0.67 |
| Sleep Apnea | 0.2 | 0 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | |
| Stress / posttraumatic stress disorder | 0.5 | 0 | 0 |
| Systemic Lupus Erythematosus | 1 | 0.3 | 2.33 |
| Tic Disorder | 0.2 | 0.2 | |
| Type 1 Diabetes | 0.4 | 0.1 | 3 |
| Type 2 Diabetes | 1.5 | 0.9 | 0.67 |
| Ulcerative colitis | 0.5 | 0.3 | 0.67 |
| Unhealthy Ageing | 1.3 | 0 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.